Feb 13, 2017 05:02 PM IST | Source: Moneycontrol.com
Buy Aurobindo Pharma; target of Rs 965: ICICI Direct
ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 965 in its research report dated February 13, 2017.
ICICI Direct's research report on Aurobindo Pharma
After filing its first ANDA in the US in 2003, the company has come a long way as the current ANDA filings are at 421. The US revenue run rate has grown from US$100 million in FY09 to US$935 million as on FY16. Note that this was despite the USFDA embargo in FY12-13 on unit VI and unit III.
We believe launches continuum, especially in the injectable space, can effectively neutralised channel consolidation and pricing pressure headwinds. Other important segment i.e. Europe is likely to fetch better margins on the back of product transfers to India and focussed approach. We have ascribed a target price of Rs 965, based on 19x (earlier 20x) FY19E EPS of Rs 50.7.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.